Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore the debate of cash back vs. points to determine which rewards suit your spending habits best. Make informed choices for your finances.
26,869 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Retiring with $1.5 million sounds like a win, but without a solid plan, it can still run dry. This guide delivers pra...
Nvidia publicly praising Marvell Technology sparked a sharp price move and fresh debate about AI-driven growth. This ...
A 1.2 million 401(K) balance at age 60 faces a harsh math problem before Medicare kicks in: high taxes, shrinking ACA...
A USD EM bond ETF is delivering about 5.4% yield, drawing retirees to its monthly payouts. This piece examines income...
As market conditions shift in 2026, debates over when to claim Social Security intensify. Suze Orman right about dela...
Markets are at new highs, and investors wonder if it’s time to buy the Vanguard S&P 500 ETF. This guide breaks down t...
A 62-year-old couple with $2.3 million in a 401(k) faces a tax-efficient choice: Roth conversions. This report breaks...
Strategy disclosed a new Bitcoin sale as part of its renewed capital plan. Far from signaling weakness, the move coul...
Rivian readies its lower-cost R2 for April deliveries, a pivotal move as analysts weigh its power to expand beyond pr...
Disney, McDonald’s, Microsoft, and Procter & Gamble now appear oversold despite solid earnings and durable consumer s...
This week, strategy (formerly microstrategy) stock dropped sharply as Bitcoin volatility clashed with treasury moves....